The estimated Net Worth of Andrew John Partridge is at least 2.81 百万$ dollars as of 9 February 2022. Mr Partridge owns over 221 units of Turning Point Therapeutics Inc stock worth over 1,678,149$ and over the last 4 years he sold TPTX stock worth over 148,010$. In addition, he makes 979,041$ as Exec. VP & Chief Commercial Officer at Turning Point Therapeutics Inc.
Mr has made over 2 trades of the Turning Point Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 221 units of TPTX stock worth 8,022$ on 9 February 2022.
The largest trade he's ever made was selling 1,869 units of Turning Point Therapeutics Inc stock on 14 July 2021 worth over 139,988$. On average, Mr trades about 523 units every 53 days since 2020. As of 9 February 2022 he still owns at least 22,078 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Mr Partridge stock trades at the bottom of the page.
Andrew John Partridge is the Exec. VP & Chief Commercial Officer at Turning Point Therapeutics Inc.
As the Exec. VP & Chief Commercial Officer of Turning Point Therapeutics Inc, the total compensation of Mr Partridge at Turning Point Therapeutics Inc is 979,041$. There are 4 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of 12,579,400$.
Mr Partridge is 52, he's been the Exec. VP & Chief Commercial Officer of Turning Point Therapeutics Inc since . There are 10 older and 9 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over 45,947,838$ worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth 60,168,920$ . The most active insiders traders include Plc Gsk、Patrick Machado、Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,727,594$. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth 88,654$.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: